On November 26, 2020 In Elekta reported that second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances (Press release, Elekta
, NOV 26, 2020, View Source [SID1234571802]). We also improved margins and stabilized cash flow. The launch of our new Harmony linac and regulatory clearances enhanced our product portfolio and strengthened our ability to deliver on our strategy of Precision Radiation Medicine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Gustaf Salford
President and CEO
Second quarter
Covid-19 continued to have a negative impact on Elekta’s growth in the quarter
Gross order intake amounted to SEK 3,627 M (4,036), corresponding to a 2 percent decrease in constant currency
Net sales were SEK 3,534 M (3,709), corresponding to a 3 percent growth in constant currency
Gross margin amounted to 40.9 (41.0) percent
EBITA increased by 39 percent to SEK 752 M (539), corresponding to an EBITA margin of 21.3 percent (14.5)
Earnings per share was SEK 0.98 (0.58) before/after dilution
Cash flow after continuous investments improved by SEK 128 M to SEK 362 M (234)
Launch of a new linac solution, Harmony
First six months
Gross order intake amounted to SEK 8,078 M (8,426), corresponding to a 1 percent growth in constant currency
Net sales were SEK 6,515 M (6,937), corresponding to a 1 percent decrease in constant currency
Gross margin amounted to 43.2 (41.7) percent
EBITA amounted to SEK 1,303 M (987), corresponding to an EBITA margin of 20.0 percent (14.2)
Earnings per share was SEK 1.55 (0.96) before/after dilution
Cash flow after continuous investments improved by SEK 939 M to SEK 389 M (-550)
Significant events after the quarter
The Board of Director has appointed Gustaf Salford as Elekta’s President and CEO with immediate effect.
Introduction of Elekta Studio with the ImagingRing providing a complete image-guided brachytherapy workflow to a single room.
1 After continuous investments.
2 Before / after dilution.
3 Based on constant currency.